Breakthrough discovery unveils potential treatment for hepatitis B

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center (MSK), Weill Cornell Medicine and The Rockefeller University identified a vulnerability that opens the door to new treatments. The team successfully disrupted the… Continue reading Breakthrough discovery unveils potential treatment for hepatitis B

Pyrazolo[3,4-d]pyrimidine-based neplanocin analogues identified as potential de novo pharmacophores for dual-target HBV inhibition

The discovery of selective and potent inhibitors through de novo pathways is essential to combat drug resistance in chronic hepatitis B (CHB) infections. Recent studies have highlighted that neplanocin A (NepA) derivatives are biologically selective inhibitors of the hepatitis B virus (HBV). In this study, we designed, synthesized, and evaluated various pyrazolo[3,4-d]pyrimidine-based NepA analogues (4a–h)… Continue reading Pyrazolo[3,4-d]pyrimidine-based neplanocin analogues identified as potential de novo pharmacophores for dual-target HBV inhibition

TWiV 1193: HPV or not to B

TWiV reviews a facility accident that killed monkeys, new bird blu genotype found in Nevada dairy cattle, Argentina plans to leave WHO, yellow fever on the rise, dynamics of HPV infections in women, and Epstein-Barr virus protein targets B cell receptor for degradation. Hosts: Vincent Racaniello, Alan Dove, and Angela Mingarelli Click arrow to playDownload TWiV… Continue reading TWiV 1193: HPV or not to B